82 FR 6644 - Certain Sleep-Disordered Breathing Treatment Systems and Components Thereof; Commission Determination to Review In-Part a Final Initial Determination on Remand, and on Remand To Affirm With Modification; Vacatur of Suspended Remedial Orders; and Termination of the Investigation

INTERNATIONAL TRADE COMMISSION

Federal Register Volume 82, Issue 12 (January 19, 2017)

Page Range		6644-6645
FR Document		2017-01143

Notice is hereby given that the U.S. International Trade Commission has determined to review in-part the presiding Administrative Law Judge's (``ALJ'') final initial determination on remand (``RID'') for the limited purpose of modifying pages 20-21 and 24 of the RID. The Commission has also determined to vacate the issued remedial orders, which are currently suspended.

Federal Register, Volume 82 Issue 12 (Thursday, January 19, 2017)

[Federal Register Volume 82, Number 12 (Thursday, January 19, 2017)]
[Notices]
[Pages 6644-6645]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-01143]


=======================================================================
-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-890 (Remand)]


Certain Sleep-Disordered Breathing Treatment Systems and 
Components Thereof; Commission Determination to Review In-Part a Final 
Initial Determination on Remand, and on Remand To Affirm With 
Modification; Vacatur of Suspended Remedial Orders; and Termination of 
the Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission has determined to review in-part the presiding 
Administrative Law Judge's (``ALJ'') final initial determination on 
remand (``RID'') for the limited purpose of modifying pages 20-21 and 
24 of the RID. The Commission has also determined to vacate the issued 
remedial orders, which are currently suspended.

FOR FURTHER INFORMATION CONTACT: Panyin A. Hughes, Office of the 
General Counsel, U.S. International Trade Commission, 500 E Street SW., 
Washington, DC 20436, telephone (202) 205-3042. Copies of non-
confidential documents filed in connection with this investigation are 
or will be available for inspection during official business hours 
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. 
International Trade Commission, 500 E Street SW., Washington, DC 20436, 
telephone (202) 205-2000. General information concerning the Commission 
may also be obtained by accessing its Internet server (https://www.usitc.gov). The public record for this investigation may be viewed 
on the Commission's electronic docket (EDIS) at https://edis.usitc.gov. 
Hearing-impaired persons are advised that information on this matter 
can be obtained by contacting the Commission's TDD terminal on (202) 
205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation 
on August 23, 2013, based on a complaint filed by ResMed Corporation of 
San Diego, California; ResMed Incorporated of San Diego, California; 
and ResMed Limited of New South Wales, Australia (collectively, 
``ResMed''). 78 FR 52564 (Aug. 23, 2013). The complaint alleged 
violations of section 337 of the Tariff Act of 1930 (19 U.S.C. 1337) in 
the importation into the United States, the sale for importation, and 
the sale within the United States after importation of certain sleep-
disordered breathing treatment systems and components thereof that 
infringe one or more of claims 32-37, 53, 79, 80, and 88 of U.S. Patent 
No. 7,997,267 (``the '267 patent''); claims 1-7 of U.S. Patent No. 
7,614,398 (``the '398 patent''); claim 1 of U.S. Patent No. 7,938,116 
(``the '116 patent''); claims 30, 37, and 38 of U.S. Patent No. 
7,341,060 (the '060 patent); claims 1, 3, 5, 11, 28, 30, 31, and 56 of 
U.S. Patent No. 8,312,883 (``the '883 patent''); claims 1, 3, 6, 7, 9, 
29, 32, 35, 40, 42, 45, 50, 51, 56, 59, 89, 92, 94, and 96 of U.S. 
Patent No. 7,178,527 (the '527 patent); claims 19-24, 26, 29-36, and 
39-41 of U.S. Patent No. 7,950,392 (the '392 patent); and claims 13, 
15, 16, 26-28, 51, 52, and 55 of U.S. Patent No 7,926,487 (``the '487 
patent''). The following patents are collectively referred to as the 
mask patents: the '527 patent; the '392 patent; the '267 patent; the 
'060 patent; and the'883 patent. The notice of investigation named the 
following respondents: BMC Medical Co., Ltd. of Beijing, China; 3B 
Medical, Inc. of Lake Wales, Florida; and 3B Products, L.L.C., of Lake 
Wales, Florida (collectively ``BMC''). The Office of Unfair Import 
Investigations (``OUII'') participated in the investigation.
    On January 9, 2014, the ALJ issued an initial determination 
(``ID'') granting a motion by ResMed to amend the complaint and notice 
of investigation to substitute U.S. Patent No. RE 44,453 (``the '453 
patent'') for the '398 patent and to terminate the investigation as to 
the '398 patent. See Order No. 7 (Jan. 9, 2014). The Commission 
determined not to review the ID. See Commission Notice of Non-Review 
(Feb. 10, 2014); 79 FR 9000-01 (Feb. 14, 2014).
    On February 24, 2014, the ALJ issued an ID granting a motion by 
ResMed to withdraw its allegations with respect to the '116 patent. See 
Order No. 11 (Feb. 24, 2014). The Commission determined not to review 
the ID. See Commission Notice of Non-Review (March 11, 2014). On March 
18, 2014, the ALJ granted a motion by ResMed to terminate the 
investigation as to claims 26-28 of the '487 Patent. See Order No. 20 
(Mar 18, 2012). The Commission determined not to review the ID. See 
Commission Notice of Non-Review (Apr. 29, 2014).
    On August 21, 2014, the ALJ issued a final ID, finding a violation 
of section 337 by BMC with respect to certain asserted claims of the 
'392, '267, '060, '883, '527, and '453 patents. The ALJ found no 
violation of section 337 with respect to the asserted claims of the 
'487 patent.
    On September 3, 2014, the parties filed petitions for review of the 
ID. On September 11, 2014, the parties filed responses to the petitions 
for review.
    On October 16, 2014, the Commission determined to review the final 
ID in part. 79 FR 63163-65 (Oct. 22, 2014). On review, the Commission 
determined to affirm the ALJ's finding of violation of section 337. The 
Commission, however, found the '453 patent invalid for anticipation. 
Having found a violation of section 337, the Commission determined that 
the appropriate form of relief was (1) a limited exclusion order 
prohibiting the unlicensed entry of sleep-disordered breathing 
treatment systems and components thereof that infringe one or more of 
claims 1, 9, 32, 89, and 92 of the '527 patent; claims 19, 21, 29, 32, 
and 36 of the '392 patent; claims 32, 33, 34, and 53 of the '267 
patent; claims 30, 37, and 38 of the '060 patent; and claims 1, 3, 5, 
11, 28, 30, 31, and 56 of the '883 patent that are manufactured by, or 
on behalf of, or are imported by or on behalf of BMC Medical Co., Ltd., 
3B Medical, Inc., or 3B Products L.L.C. or any of their affiliated 
companies, parents, subsidiaries, agents, or other related business 
entities, or their successors or assigns, except for service

[[Page 6645]]

and replacement parts for customers that purchased their covered 
products prior to the date the exclusion order becomes final; and (2) 
cease and desist orders prohibiting domestic respondents BMC Medical 
Co., Ltd., 3B Medical, Inc. from conducting any of the following 
activities in the United States: Importing, selling, marketing, 
advertising, distributing, transferring (except for exportation), and 
soliciting U.S. agents or distributors for, sleep-disordered breathing 
treatment systems and components thereof covered by claims 1, 9, 32, 
89, and 92 of the '527 patent; claims 19, 21, 29, 32, and 36 of the 
'392 patent; claims 32, 33, 34, and 53 of the '267 patent; claims 30, 
37, and 38 of the '060 patent; and claims 1, 3, 5, 11, 28, 30, 31, and 
56 of the '883 patent.
    On February 18, 2015, ResMed filed a notice of appeal in the U.S. 
Court of Appeals for the Federal Circuit, seeking review of the 
Commission's determination as to the '453 patent (Appeal No. 2015-
1360). On April 14, 2015, BMC filed a notice of appeal in the Federal 
Circuit, seeking review of the Commission's domestic industry 
determination as well as the Commission's finding that prior art does 
not render the asserted claims of the '267 patent invalid for 
obviousness (Appeal No. 2015-1576). The Court consolidated the two 
appeals on April 23, 2015.
    On March 16, 2016, the parties jointly moved to dismiss ResMed's 
appeal as to the '453 patent. On March 17, 2016, the Commission moved 
to remand BMC's appeal in light of intervening domestic industry 
precedent in Lelo Inc. v. International Trade Commisson, 789 F.3d 879 
(Fed. Cir. 2015). On March 29, 2016, the Court granted the motion to 
dismiss ResMed's appeal. On April 22, 2016, the Court granted the 
Commission's remand motion.
    On May 12, 2016, the Commission issued a notice suspending the 
remedial orders in place during the pendency of the remand proceedings. 
81 FR 31254-55 (May 18, 2016). The Commission also issued an order 
asking the parties to comment on further proceedings. On June 8, 2016, 
the parties submitted initial comments. The parties filed responses on 
July 15, 2016. On August 16, 2016, the Commission issued an order 
remanding the investigation to the ALJ to: (1) Apply the Federal 
Circuit's intervening domestic industry precedent in Lelo to the 
existing record (as to the mask patents, the only patents remaining); 
and (2) issue an RID on remand as to violation.
    On November 10, 2016, the ALJ issued the RID finding that ResMed 
failed to establish the existence of a domestic industry that practices 
the mask patents. RID at 1. No petitions for review were received.
    Having examined the record of this investigation, the Commission 
has determined to review in-part the RID for the limited purpose of 
modifying pages 20-21 and 24 of the RID. The Commission does not adopt 
the RID's statements that ``the amount a complainant spends to purchase 
components manufactured in the United States is immaterial to the 
economic prong analysis'' (RID at 20-21) or that evidence of payments 
to domestic suppliers is ``per se insufficient to include in the 
quantitative analysis.'' RID at 24. The Commission has determined to 
otherwise not review the RID. The Commission has determined to vacate 
the suspended remedial orders. The investigation is terminated.
    The authority for the Commission's determination is contained in 
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and 
in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR 
part 210).

    By order of the Commission.

    Issued: January 12, 2017.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2017-01143 Filed 1-18-17; 8:45 am]
 BILLING CODE 7020-02-P

6644 Federal Register / Vol. 82, No. 12 / Thursday, January 19, 2017 / Notices

Decision (ROD). The ROD is available at Counsel, U.S. International Trade Unfair Import Investigations (‘‘OUII’’)
boemoceaninfo.com. Commission, 500 E Street SW., participated in the investigation.
FOR FURTHER INFORMATION CONTACT: Jill Washington, DC 20436, telephone (202) On January 9, 2014, the ALJ issued an
Lewandowski, Ph.D., Bureau of Ocean 205–3042. Copies of non-confidential initial determination (‘‘ID’’) granting a
Energy Management, 45600 Woodland documents filed in connection with this motion by ResMed to amend the
Road VAM–OEP, Sterling, VA 20166. investigation are or will be available for complaint and notice of investigation to
Dr. Lewandowski may also be reached inspection during official business substitute U.S. Patent No. RE 44,453
by telephone at (703) 787–1703. hours (8:45 a.m. to 5:15 p.m.) in the (‘‘the ’453 patent’’) for the ’398 patent
Office of the Secretary, U.S. and to terminate the investigation as to
SUPPLEMENTARY INFORMATION: In
International Trade Commission, 500 E the ’398 patent. See Order No. 7 (Jan. 9,
accordance with 40 CFR 1505.2, the 2014). The Commission determined not
Bureau of Ocean Energy Management Street SW., Washington, DC 20436,
telephone (202) 205–2000. General to review the ID. See Commission
(BOEM) announces the availability of Notice of Non-Review (Feb. 10, 2014);
the 2017–2022 Outer Continental Shelf information concerning the Commission
may also be obtained by accessing its 79 FR 9000–01 (Feb. 14, 2014).
(OCS) Oil and Gas Leasing Program On February 24, 2014, the ALJ issued
Final Programmatic EIS (Final Internet server (https://www.usitc.gov).
The public record for this investigation an ID granting a motion by ResMed to
Programmatic EIS) Record of Decision withdraw its allegations with respect to
(ROD). The ROD is available at may be viewed on the Commission’s
electronic docket (EDIS) at https:// the ’116 patent. See Order No. 11 (Feb.
boemoceaninfo.com. 24, 2014). The Commission determined
The Final Programmatic EIS was edis.usitc.gov. Hearing-impaired
persons are advised that information on not to review the ID. See Commission
published on November 25, 2016 (81 FR Notice of Non-Review (March 11, 2014).
85221). BOEM considered comments this matter can be obtained by
contacting the Commission’s TDD On March 18, 2014, the ALJ granted a
submitted on the Final Programmatic motion by ResMed to terminate the
EIS before a final decision was made. terminal on (202) 205–1810.
investigation as to claims 26–28 of the
SUPPLEMENTARY INFORMATION: The
Authority: This Notice of Availability of ’487 Patent. See Order No. 20 (Mar 18,
a ROD is issued in accordance with the
Commission instituted this investigation 2012). The Commission determined not
National Environmental Policy Act of 1969, on August 23, 2013, based on a to review the ID. See Commission
as amended (Pub. L. 91–190, 42 U.S.C. 4231 complaint filed by ResMed Corporation Notice of Non-Review (Apr. 29, 2014).
et seq.), and implementing regulations (See of San Diego, California; ResMed On August 21, 2014, the ALJ issued a
40 CFR 1505.2). Incorporated of San Diego, California; final ID, finding a violation of section
and ResMed Limited of New South 337 by BMC with respect to certain
Walter D. Cruickshank,
Wales, Australia (collectively, asserted claims of the ’392, ’267, ’060,
Acting Director, Bureau of Ocean Energy ‘‘ResMed’’). 78 FR 52564 (Aug. 23,
Management. ’883, ’527, and ’453 patents. The ALJ
2013). The complaint alleged violations found no violation of section 337 with
[FR Doc. 2017–00886 Filed 1–18–17; 8:45 am]
of section 337 of the Tariff Act of 1930 respect to the asserted claims of the ’487
BILLING CODE 4310–MR–P (19 U.S.C. 1337) in the importation into patent.
the United States, the sale for On September 3, 2014, the parties
importation, and the sale within the filed petitions for review of the ID. On
INTERNATIONAL TRADE United States after importation of September 11, 2014, the parties filed
COMMISSION certain sleep-disordered breathing responses to the petitions for review.
treatment systems and components On October 16, 2014, the Commission
[Investigation No. 337–TA–890 (Remand)]
thereof that infringe one or more of determined to review the final ID in
Certain Sleep-Disordered Breathing claims 32–37, 53, 79, 80, and 88 of U.S. part. 79 FR 63163–65 (Oct. 22, 2014).
Treatment Systems and Components Patent No. 7,997,267 (‘‘the ’267 patent’’); On review, the Commission determined
Thereof; Commission Determination to claims 1–7 of U.S. Patent No. 7,614,398 to affirm the ALJ’s finding of violation
Review In-Part a Final Initial (‘‘the ’398 patent’’); claim 1 of U.S. of section 337. The Commission,
Determination on Remand, and on Patent No. 7,938,116 (‘‘the ’116 patent’’); however, found the ’453 patent invalid
Remand To Affirm With Modification; claims 30, 37, and 38 of U.S. Patent No. for anticipation. Having found a
Vacatur of Suspended Remedial 7,341,060 (the ’060 patent); claims 1, 3, violation of section 337, the
Orders; and Termination of the 5, 11, 28, 30, 31, and 56 of U.S. Patent Commission determined that the
Investigation No. 8,312,883 (‘‘the ’883 patent’’); appropriate form of relief was (1) a
claims 1, 3, 6, 7, 9, 29, 32, 35, 40, 42, limited exclusion order prohibiting the
AGENCY: U.S. International Trade 45, 50, 51, 56, 59, 89, 92, 94, and 96 of unlicensed entry of sleep-disordered
Commission. U.S. Patent No. 7,178,527 (the ’527 breathing treatment systems and
ACTION: Notice. patent); claims 19–24, 26, 29–36, and components thereof that infringe one or
39–41 of U.S. Patent No. 7,950,392 (the more of claims 1, 9, 32, 89, and 92 of
SUMMARY: Notice is hereby given that ’392 patent); and claims 13, 15, 16, 26– the ’527 patent; claims 19, 21, 29, 32,
the U.S. International Trade 28, 51, 52, and 55 of U.S. Patent No and 36 of the ’392 patent; claims 32, 33,
Commission has determined to review 7,926,487 (‘‘the ’487 patent’’). The 34, and 53 of the ’267 patent; claims 30,
in-part the presiding Administrative following patents are collectively 37, and 38 of the ’060 patent; and claims
Law Judge’s (‘‘ALJ’’) final initial referred to as the mask patents: the ’527 1, 3, 5, 11, 28, 30, 31, and 56 of the ’883
determination on remand (‘‘RID’’) for patent; the ’392 patent; the ’267 patent; patent that are manufactured by, or on
mstockstill on DSK3G9T082PROD with NOTICES

the limited purpose of modifying pages the ’060 patent; and the’883 patent. The behalf of, or are imported by or on
20–21 and 24 of the RID. The notice of investigation named the behalf of BMC Medical Co., Ltd., 3B
Commission has also determined to following respondents: BMC Medical Medical, Inc., or 3B Products L.L.C. or
vacate the issued remedial orders, Co., Ltd. of Beijing, China; 3B Medical, any of their affiliated companies,
which are currently suspended. Inc. of Lake Wales, Florida; and 3B parents, subsidiaries, agents, or other
FOR FURTHER INFORMATION CONTACT: Products, L.L.C., of Lake Wales, Florida related business entities, or their
Panyin A. Hughes, Office of the General (collectively ‘‘BMC’’). The Office of successors or assigns, except for service

VerDate Sep<11>2014 21:20 Jan 18, 2017 Jkt 241001 PO 00000 Frm 00163 Fmt 4703 Sfmt 4703 E:\FR\FM\19JAN1.SGM 19JAN1

Federal Register / Vol. 82, No. 12 / Thursday, January 19, 2017 / Notices 6645

and replacement parts for customers failed to establish the existence of a exercise all necessary functions with
that purchased their covered products domestic industry that practices the respect to the promulgation and
prior to the date the exclusion order mask patents. RID at 1. No petitions for implementation of 21 CFR part 1301,
becomes final; and (2) cease and desist review were received. incident to the registration of
orders prohibiting domestic respondents Having examined the record of this manufacturers, distributors, dispensers,
BMC Medical Co., Ltd., 3B Medical, Inc. investigation, the Commission has importers, and exporters of controlled
from conducting any of the following determined to review in-part the RID for substances (other than final orders in
activities in the United States: the limited purpose of modifying pages connection with suspension, denial, or
Importing, selling, marketing, 20–21 and 24 of the RID. The revocation of registration) has been
advertising, distributing, transferring Commission does not adopt the RID’s redelegated to the Assistant
(except for exportation), and soliciting statements that ‘‘the amount a Administrator of the DEA Diversion
U.S. agents or distributors for, sleep- complainant spends to purchase
disordered breathing treatment systems Control Division (‘‘Assistant
components manufactured in the United
and components thereof covered by Administrator’’) pursuant to section 7 of
States is immaterial to the economic
claims 1, 9, 32, 89, and 92 of the ’527 28 CFR part 0, appendix to subpart R.
prong analysis’’ (RID at 20–21) or that
patent; claims 19, 21, 29, 32, and 36 of evidence of payments to domestic In accordance with 21 CFR
the ’392 patent; claims 32, 33, 34, and suppliers is ‘‘per se insufficient to 1301.33(a), this is notice that on July 12,
53 of the ’267 patent; claims 30, 37, and include in the quantitative analysis.’’ 2016, Noramco, Inc., 500 Swedes
38 of the ’060 patent; and claims 1, 3, RID at 24. The Commission has Landing Road, Wilmington, Delaware
5, 11, 28, 30, 31, and 56 of the ’883 determined to otherwise not review the 19801–4417 applied to be registered as
patent. RID. The Commission has determined to a bulk manufacturer of the following
On February 18, 2015, ResMed filed a vacate the suspended remedial orders. basic classes of controlled substances:
notice of appeal in the U.S. Court of The investigation is terminated.
Appeals for the Federal Circuit, seeking The authority for the Commission’s Drug
review of the Commission’s Controlled substance Schedule
determination is contained in section code
determination as to the ’453 patent 337 of the Tariff Act of 1930, as
(Appeal No. 2015–1360). On April 14, amended (19 U.S.C. 1337), and in Part Marihuana ................. 7360 I
2015, BMC filed a notice of appeal in 210 of the Commission’s Rules of Codeine-N-oxide ....... 9053 I
the Federal Circuit, seeking review of Practice and Procedure (19 CFR part Dihydromorphine ...... 9145 I
the Commission’s domestic industry 210). Hydromorphinol ........ 9301 I
determination as well as the Morphine-N-oxide ..... 9307 I
Commission’s finding that prior art does By order of the Commission. Amphetamine ........... 1100 II
not render the asserted claims of the Issued: January 12, 2017. Methylphenidate ....... 1724 II
’267 patent invalid for obviousness Lisa R. Barton, Phenylacetone .......... 8501 II
(Appeal No. 2015–1576). The Court Secretary to the Commission. Codeine .................... 9050 II
consolidated the two appeals on April [FR Doc. 2017–01143 Filed 1–18–17; 8:45 am] Dihydrocodeine ......... 9120 II
23, 2015. BILLING CODE 7020–02–P
Oxycodone ............... 9143 II
On March 16, 2016, the parties jointly Hydromorphone ........ 9150 II
moved to dismiss ResMed’s appeal as to Hydrocodone ............ 9193 II
the ’453 patent. On March 17, 2016, the DEPARTMENT OF JUSTICE
Morphine ................... 9300 II
Commission moved to remand BMC’s Oripavine .................. 9330 II
appeal in light of intervening domestic Drug Enforcement Administration Thebaine ................... 9333 II
industry precedent in Lelo Inc. v. Opium extracts ......... 9610 II
International Trade Commisson, 789 [Docket No. DEA–392] Opium fluid extract ... 9620 II
F.3d 879 (Fed. Cir. 2015). On March 29, Opium tincture .......... 9630 II
Bulk Manufacturer of Controlled Opium, powdered ..... 9639 II
2016, the Court granted the motion to
Substances Application: Noramco, Inc. Opium, granulated .... 9640 II
dismiss ResMed’s appeal. On April 22,
2016, the Court granted the Oxymorphone ........... 9652 II
ACTION: Notice of application.
Commission’s remand motion. Noroxymorphone ...... 9668 II
On May 12, 2016, the Commission Tapentadol ................ 9780 II
DATES: Registered bulk manufacturers of
issued a notice suspending the remedial the affected basic classes, and
orders in place during the pendency of applicants therefore, may file written The company plans to manufacture
the remand proceedings. 81 FR 31254– comments on or objections to the the above-listed controlled substances
55 (May 18, 2016). The Commission also issuance of the proposed registration in in bulk for distribution to its customers.
issued an order asking the parties to accordance with 21 CFR 1301.33(a) on In reference to drug code 7360, the
comment on further proceedings. On or before March 20, 2017. company plans to manufacture a
June 8, 2016, the parties submitted synthetic version of cannabidiol in bulk
ADDRESSES: Written comments should
initial comments. The parties filed for sale to its customers, who are final
be sent to: Drug Enforcement
responses on July 15, 2016. On August
Administration, Attention: DEA Federal dosage form manufacturers. No other
16, 2016, the Commission issued an
Register Representative/DRW, 8701 activity for this drug code is authorized
order remanding the investigation to the
Morrissette Drive, Springfield, Virginia for this registration.
ALJ to: (1) Apply the Federal Circuit’s
mstockstill on DSK3G9T082PROD with NOTICES

22152.
intervening domestic industry Dated: January 11, 2017.
precedent in Lelo to the existing record SUPPLEMENTARY INFORMATION: The Louis J. Milione,
(as to the mask patents, the only patents Attorney General has delegated her Assistant Administrator.
remaining); and (2) issue an RID on authority under the Controlled
[FR Doc. 2017–01103 Filed 1–18–17; 8:45 am]
remand as to violation. Substances Act to the Administrator of
BILLING CODE 4410–09–P
On November 10, 2016, the ALJ the Drug Enforcement Administration
issued the RID finding that ResMed (DEA), 28 CFR 0.100(b). Authority to

VerDate Sep<11>2014 21:20 Jan 18, 2017 Jkt 241001 PO 00000 Frm 00164 Fmt 4703 Sfmt 9990 E:\FR\FM\19JAN1.SGM 19JAN1

Document Created: 2018-02-01 15:15:47
Document Modified: 2018-02-01 15:15:47

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Contact		Panyin A. Hughes, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205-3042. Copies of non- confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205-2000. General information concerning the Commission may also be obtained by accessing its Internet server (https:// www.usitc.gov). The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at https://edis.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810.
FR Citation		82 FR 6644